P

Plus Therapeutics
D

PSTV

0.52330
USD
-0.01
(-2.66%)
مغلق
حجم التداول
0
الربح لكل سهم
-1
العائد الربحي
-
P/E
-0
حجم السوق
31,654,470
أصول ذات صلة
AAPL
AAPL
-0.350
(-0.15%)
230.540 USD
AMZN
AMZN
-3.430
(-1.48%)
228.010 USD
CMCSA
CMCSA
0.485
(1.45%)
33.900 USD
DIS
DIS
-0.285
(-0.24%)
116.290 USD
GOOGL
GOOGL
-1.840
(-0.90%)
201.600 USD
NFLX
NFLX
-30.64
(-2.46%)
1,214.37 USD
ROKU
ROKU
-3.450
(-3.74%)
88.880 USD
T
T
0.070
(0.24%)
28.985 USD
المزيد
الأخبار المقالات

العنوان: Plus Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).